- Market Capitalization, $K 58,854
- Shares Outstanding, K 13,751
- Annual Sales, $ 96,430 K
- Annual Income, $ -157,190 K
- 60-Month Beta 4.54
- Price/Sales 0.62
- Price/Cash Flow N/A
- Price/Book 0.36
|Period||Period Low||Period High||Performance|
| || |
+1.05 (+32.51%)since 09/18/19
| || |
+0.35 (+8.91%)since 07/18/19
| || |
-14.72 (-77.47%)since 10/18/18
The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies...
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer...
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -19.46% and 13.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes...
~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~
~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Melinta Therapeutics, Inc. (MLNT) closed at $4.07 in the latest trading session, marking a -0.49% move from the prior day.